


PRODUCT INFORMATION



13,14-dihydro-15-keto Prostaglandin J₂

Item No. 10008840

CAS Registry No.: 2230717-14-1
Formal Name: 11,15-dioxo-prosta-5Z,9-dien-1-oic acid
MF: C₂₀H₃₀O₄
FW: 334.5
Purity: ≥97%
Supplied as: A solution in methyl acetate
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

13,14-dihydro-15-keto Prostaglandin J₂ (PGJ₂) is supplied as a solution in methyl acetate. To change the solvent, simply evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of 13,14-dihydro-15-keto PGJ₂ in these solvents is approximately 50 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of 13,14-dihydro-15-keto PGJ₂ is needed, it can be prepared by evaporating the methyl acetate and directly dissolving the neat oil in aqueous buffers. The solubility of 13,14-dihydro-15-keto PGJ₂ in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Various biological properties exist for both PGJ₂ and its metabolites such as inhibition of platelet aggregation, antitumor, and antiviral activity.^{1,2} 13,14-dihydro-15-keto PGJ₂ is the dehydration product of 13,14-dihydro-15-keto PGD₂ and is a presumed metabolite of PGJ₂ via the 15-hydroxy PG dehydrogenase pathway. There are no published studies of the pharmacological properties or the formation of 13,14-dihydro-15-keto PGJ₂ *in vivo*.

References

1. Bundy, G.L., Morton, D.R., Peterson, D.C., *et al.* Synthesis and platelet aggregation inhibiting activity of prostaglandin D analogues. *J. Med. Chem.* **26**, 70-799 (1983).
2. Kato, T., Fukushima, M., Kurozumi, S., *et al.* Antitumor activity of Δ⁷-prostaglandin A₁ and Δ¹²-prostaglandin J₂ *in vitro* and *in vivo*. *Cancer Res.* **46**, 3538-3542 (1986).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM